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Purpose: To screen the myocilin (MYOC) and forkhead box protein C1 (FOXC1) genes for sequence variations in primary
congenital glaucoma (PCG).
Methods: Seventy five PCG patients were screened for MYOC variations and 54 cases (negative or heterozygous for
cytochrome P4501B1 mutations) for FOXC1 mutations by polymerase chain reaction (PCR) and DNA sequencing.
Results: Five single nucleotide polymorphisms (SNPs; −126T>C, −83G>A, p.R76K, IVS2+35G>A, and p.Y347Y) were
identified in MYOC and two sequence variations (GGC375ins and GGC447ins) in FOXC1. No pathogenic variations were
identified in MYOC and FOXC1 in our patients.
Conclusions: MYOC and FOXC1 mutations are not involved in pathogenesis of primary congenital glaucoma in our
patients. Thus, it is important to screen other loci for involvement in congenital glaucoma in cases which are negative or
heterozygous for CYP1B1 mutations to have a better insight in to disease pathogenesis.
Glaucoma  is  an  optic  neuropathy,  characterized  by
elevated intra-ocular pressure (IOP) which results in retinal
ganglion  cell  (RGC)  death  and  vision  loss  [1].  Primary
congenital glaucoma (PCG; OMIM 231300) is a severe form
of glaucoma which manifests in the neonatal/early infantile
period  with  a  classic  triad  of  symptoms  viz.  epiphora
(excessive tearing), photophobia (hypersensitivity to light),
and  blepharospasm  [2].  The  prevalence  of  congenital
glaucoma varies across ethnic communities and geographical
boundaries [3]. In the Indian state of Andhra Pradesh, its
prevalence is estimated to be around 1:3,300 and accounts for
4.2% of all cases of childhood blindness [4].
Genetic heterogeneity is the hallmark of PCG and three
chromosomal  loci  (I)  2p21  (GLC3A  (GLC  stands  for
glaucoma); OMIM 231300) [5], (II) 1p36 (GLC3B; OMIM
600975)  [6],  and  (III)  14q24.3  (GLC3C)  [7]  have  been
mapped by linkage analysis, of which only the GLC3A locus
harboring  the  human  Cytochrome  P450  gene  (CYP1B1;
OMIM 601771) has been characterized [8]. CYP1B1 exhibits
a  high  degree  of  allelic  heterogeneity  and  more  than  79
different mutations associated with PCG have been identified
[9]. The proportion of PCG cases with CYP1B1 mutations
vary  widely  across  different  populations  and  are  highest
among the inbred Slovakian Gypsy [10] and Saudi Arabian
populations [11] which exhibit allelic homogeneity.
Earlier we reported CYP1B1 mutations as a predominant
cause  for  PCG  phenotype  [12,13].  We  observed  CYP1B1
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mutations  in  42.66%  PCG  cases  (32/75;  13  cases  were
homozygous, 8 were compound heterozygous, and 11 were
heterozygous for CYP1B1 mutations). However, 57.34% of
these cases did not show the involvement of CYP1B1.
This led us to explore the role of other genes to understand
their possible implications in the disease pathogenesis. The
myocilin gene implicated in juvenile open angle glaucoma
(JOAG)  and  in  adult-onset  primary  open  angle  glaucoma
(POAG)  [14]  was  chosen  as  the  potential  candidate  for
screening these cases. The myocilin gene (MYOC) exhibits a
wide spectrum of mutations and accounts for 2–5% cases of
POAG [15] and in 5.5% of PCG [16]. MYOC is located on
chromosome  1  at  1q25  and  codes  for  myocilin/trabecular
meshwork-induced glucocorticoid response (TIGR) protein.
Most tissues of the eye express MYOC, including trabecular
meshwork, sclera, ciliary body, and retina [17,18]. An earlier
report showed that MYOC interacts with CYP1B1 through a
digenic mechanism in causing JOAG [19].
Forkhead  box  protein  C1  (FOXC1/FKHL7),  another
gene, was also selected for mutation analysis in PCG cases
which  were  either  negative  or  heterozygous  for  CYP1B1
mutations. A recent study from Southern India has reported
involvement of FOXC1 mutations in PCG [20]. FOXC1 is a
member of the winged helix/forkhead family of transcription
factors. It is located on 6p25 and has single exon that codes
for 553 amino acids long protein [21]. The FOXC1 protein is
expressed in various ocular and non-ocular tissues [22,23] and
is found in periocular mesenchyme cells that give rise to
ocular  drainage  structures  such  as  the  iris,  cornea,  and
trabecular meshwork [24]. Both the FOXC1 null (FOXC1−/−)
and the heterozygous (FOXC1+/−) mice were found to have
anterior segment abnormalities similar to those in humans
with  anterior  segment  dysgenesis  (ASD)  and  congenital
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1996glaucoma [25]. In this study we have screened MYOC gene in
75 PCG cases and FOXC1 gene in 54 PCG cases (negative/
heterozygous for CYP1B1 mutations) to understand the role
of these two gene in the pathogenesis of this blinding disorder.
METHODS
Congenital glaucoma cases presenting at the Dr. Rajendra
Prasad Centre for Ophthalmic Sciences, All India Institute of
Medical Sciences (AIIMS), New Delhi, India, were enrolled
for  this  study.  After  ethical  approval  of  the  Institutional
Review Board (IRB00006862; AIIMS) a total of 75 PCG
cases were screened for MYOC sequence variations while
FOXC1  was  screened  in  54  cases  (either  negative  or
heterozygous for CYP1B1 mutations; Table 1). The diagnosis
involved clinical, ocular and systemic examination. Inclusion
criteria  of  the  patients  were  increased  corneal  diameter
(>12.0 mmHg) and raised IOP (>21 mmHg) with presence/
absence  of  Haab’s  striae  and  optic  disc  changes  (where
examination  was  possible).  Symptoms  of  epiphora  and
photophobia were the additional inclusion factors. The age of
onset ranged from birth to 3 years.
All patients with history of blood transfusion, TORCH
(Toxoplasmosis; Rubella; Cytomegalovirus; Herpes Simplex
Virus) infection and drug intake by mother during pregnancy
were  excluded.  Glaucoma  cases  other  than  PCG  were
excluded. Detailed family history of ocular or other hereditary
disorders up to three generations were taken, and pedigree
charts were constructed.
Control group: Seventy five ethnically matched normal
individuals  without  any  ocular/systemic  disorders  were
enrolled as controls for MYOC and 50 for FOXC1 analysis.
Peripheral blood samples were collected from patients and
controls by venipuncture in ethylenediaminetetra-acetic acid
(EDTA) vacutainers only after informed consent and stored
in −80 °C until further use.
Mutation screening and sequence analysis: DNA was
isolated  from  the  peripheral  blood  using  the  Phenol
chloroform  method.  All  three  exons  with  exon-intron
boundaries were amplified from DNA using polymerase chain
reaction  (PCR)  primers  designed  for  MYOC  (GenBank
AB006688;  available  at  Genbank)  [26].  FOXC1  primers
(Table  2)  were  designed  using  National  Center  for
Biotechnology Information (NCBI) PRIMER3 program. PCR
amplifications  for  FOXC1  primers  were  performed  in  a
40 μl volume containing 1.0 μl of 20 μM stock solution for
each  primer,  100  ng  of  genomic  DNA,  1  unit  of  Taq
polymerase (Banglore Genei P Ltd, Bengaluru, Karnataka,
India), 0.1 mM of each dNTP and 4 μl of 10× PCR buffer (with
15 mM MgCl2), by means of 35 cycles of amplification, each
consisting of 30 s denaturation at 94 °C, 50 s annealing at
56 °C −59 °C and 1 min extension at 72 °C and final extension
at 72 °C for 5 min.
All PCR products were analyzed on 1.8% agarose gel,
stained with ethidium-bromide (EtBr 10 mg/ml). Agarose gel
was  analyzed  using  gel  documentation  system  (Applied
biosystems, Carlsbad, CA). Amplified PCR products were
purified  using  gel/PCR  DNA  fragments  extraction  kit
(Catalog number DF100; Geneaid Biotech Ltd., Sijhih City,
Taiwan). Purified PCR product were sent for sequencing at
MCLAB  (Molecular  Cloning  Laboratories,  South  San
Francisco, CA). DNA sequences were analyzed against the
MYOC  reference  sequence  and  the  FOXC1  reference
sequence  using  ClustalW2  provided  by  the  European
Molecular  Biology  Laboratory  (EMBL)  European
Bioinformatics Institute (EBI).
Computational assessment of missense mutations: Two
homology  based  programs  PolyPhen  (Polymorphism
Phenotyping) and SIFT (Sorting Intolerant From Tolerant)
analysis tool were used to predict the functional impact of
missense  changes  identified  in  this  study  [27,28].  The
prediction  is  based  on  the  position-specific  independent
counts  (PSIC)  score  derived  from  multiple  sequence
alignments of observations. PolyPhen scores of >2.0 indicate
the polymorphism is probably damaging to protein function.
Scores of 1.5–2.0 are possibly damaging, and scores of <1.5
are likely benign. SIFT is a sequence homology-based tool
that sorts intolerant from tolerant amino acid substitutions and
predicts whether an amino acid substitution in a protein will
have a phenotypic effect [29,30]. Positions with normalized
probabilities less than 0.05 are predicted to be deleterious and,
those greater than or equal to 0.05 are predicted to be tolerated.
We have also used an improved splice site predictor tool
[31] to predict whether a nucleotide change is likely to create
a splice site.
Statistical  analysis:  The  frequency  of  nucleotide
variation between cases and controls was calculated by χ2/
Fisher’s  exact  test  and  a  p-value  ≤0.05  was  considered
significant.
RESULTS
A total of five nucleotide changes (2 in promoter region, 2 in
coding region and 1 in intronic region) were observed in
MYOC  and  two  sequence  variations  (GGC375ins  and
GGC447ins) were observed in FOXC1 in this study. Details
of all these changes are given below.
Myocilin (MYOC) gene:
−126  Thymine  to  Cytosine  (−126T>C)—This
nucleotide change resulted in thymine (T) being replaced by
cytosine(C; Figure 1) at position g.169888563 or 126 base
pairs upstream (−126 position). This change was homozygous
in one (PCG043) and heterozygous in one case (PCG053) but
was absent in controls.
−83 Guanine to Adenine (−83G>A)—This nucleotide
change resulted in guanine (G) being replaced by alanine (A;
Figure 2) at position g.169888457 or 83 base pairs upstream
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2001(−83 position). This change was homozygous in five cases
(PCG07, 015, 034, 040, and 062) and heterozygous (PCG06,
15, 34, and 40) in four cases. This change was also present in
2 controls.
Arginine76Lysine (p.R76K)—This nucleotide change
resulted in G being replaced by A (Figure 3) at position g.
169888148; coding nucleotide number c.127. This resulted in
a codon change from AGA to AAA and amino acid change
from arginine to lysine (p.R76K) a non-synonymous mutation
in  MYOC.  This  change  was  homozygous  in  five  patients
(PCG007, 015, 034, 040, and 052) and heterozygous in twenty
five patients (PCG005, 006, 011, 012, 0016–019, 021, 022,
027, 033, 036, 043, 044, 046, 049, 059, 062, and 065–069)
and was also present in 12 controls.
IVS2+35 Guanine to Adenine (IVS2+35G>A)—This
nucleotide change resulted in G being replaced by A (Figure
4)  at  position  g.169874325  or  35  base  pairs  downstream
(IVS2+35 position) ; This change was homozygous in forty
seven patients (PCG002, 004, 006–009, 011–013, 015, 017,
019–022, 026–029, 033–036, 039–041, 043–046, 049–060,
063–066,  and  069)  and  heterozygous  in  thirteen  patients
(PCG001, 003, 005, 010, 016, 018, 023, 037, 042, 054, 061,
062, and 067) and was also present in 25 controls.
Tyrosine347Tyrosine  (p.Y347Y)—This  mutation
resulted in T being replaced by C (Figure 5) at position g.
169872162; coding nucleotide number c.1041. This resulted
in a codon change from TAT to TAC with no amino acid
change (synonymous mutation) at 347 (p.Y347Y) in MYOC
protein. Five cases (PCG029, 036, 043, 053, and 056) were
heterozygous for this change while the same was absent in
controls. All MYOC sequencing results have been tabulated
(Table 3).
Forkhead box protein C1 (FOXC1) gene:
Insertion  of  GCG  at  g.1556820—Insertion  of  tri-
nucleotide GCG at g.1556820 was observed in nine PCG
cases (PCG006–008, 011, 023, 048, 051, 054, and 072) and
TABLE 2. FOXC1 PRIMERS USED IN THIS STUDY.
Serial number Primer sequence Product size
1 1F- CCCGGACTCGGACTCGGC 649 bp
  1R- TCTCCTCCTTGTCCTTCACC  
2 2F- GAGAACGGCAGCTTCCTG 708 bp
  2R-TTGCAGGTTGCAGTGGTAGGT  
3 3F-GGCCAGAGCTCCCTCTACA 636 bp
  3R-CTGCTTTGGGGTTCGATTTA  
Figure 1. DNA sequence chromatogram of MYOC equivalent to bases −121 to −132. A: The reference sequence derived from control is shown.
B: Sequence derived from congenital glaucoma patient PCG043 shows heterozygous −126T>C nucleotide change.
Figure 2. DNA sequence chromatogram of MYOC equivalent to bases −76 to −88. A: The reference sequence derived from control is shown.
B: Sequence derived from congenital glaucoma patient PCG015 shows homozygous −83G>A nucleotide change.
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2002four controls. This insertion was found in both alleles. This
caused an insertion of an extra GGC triplet and an extra amino
acid  glycine  at  position  375  (GGC375ins).  This  leads  to
presence of seven glycine residues (generally six glycine are
found) at amino acid position 375–381 instead of six glycine
residues.
Insertion  of  CGG  at  g.1557040—Homozygous
insertion of tri-nucleotide CGG at g.1557040 was observed in
six PCG cases (PCG006, 007, 051, 059, 063, and 065) and
five controls. This caused an insertion of an extra GGC triplet
which  inserts  an  extra  amino  acid  glycine  at  amino  acid
position 447 (GGC447ins). This leads to presence of eleven
glycine residues at amino acid position 447–457.
Three  PCG  cases  (PCG006,  007,  and  051)  had  both
insertions (GGC375ins and GGC447ins). No other changes
were identified in any PCG patient. All FOXC1 variations
have been tabulated (Table 4).
SIFT  and  PolyPhen  analysis:  There  was  only  one
missense change in MYOC in our study. The PSIC score of
the p.R76K mutation was <2 indicating that this change was
benign to protein function. The SIFT score of p.R76K was
0.00  and  was  predicted  to  be  deleterious  for  the  protein
function. Ideally, to call a change pathogenic both SIFT and
PolyPhen results should be pathogenic. Since this change was
present both in PCG and controls, it could be hypothesized
that  this  change  is  non-pathogenic.  Improved  splice  site
prediction  for  IVS2+35G>A  showed  that  this  location
(IVS2+35) is not present at splice site and may not create a
splicing error in MYOC.
Figure 3. DNA sequence chromatogram of MYOC exon 1 equivalent to codon 75–78. A: The reference sequence derived from control is
shown. B: Sequence derived from congenital glaucoma patient PCG005 shows homozygous c.127G>A, which predicts a codon change
AGA>AAA and p.R76K change.
Figure 4. DNA sequence chromatogram of MYOC equivalent to IVS2+31 to IVS2+42 A: The reference sequence derived from control is
shown. B: Sequence derived from congenital glaucoma patient PCG004 shows homozygous IVS2+35G>A nucleotide change.
Figure 5. DNA sequence chromatogram of MYOC exon 3 equivalent to codon 346–348. A: The reference sequence derived from control is
shown. B: Sequence derived from congenital glaucoma patient PCG029 shows heterozygous c.1041T>C, which predicts a codon change
TAT>TAC and p.Y347Y change.
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2003DISCUSSION
PCG  shows  marked  genetic  heterogenity  thus  we  have
 screened MYOC in 75 PCG cases to study digenic inheritance
and  FOXC1  in  54  cases  which  were  either  negative  or
heterozygous for the CYP1B1 mutation for their involvement.
To the best of our knowledge this is the first study from north
India which involves MYOC and FOXC1 screening in PCG.
In our study three single nucleotide polymorphisms (SNPs;
Table 3) were observed both in PCG cases as well as in
controls while two were limited to cases only. The frequency
of p.R76K, IVS2+35G>A, and p.Y347Y in MYOC was found
to be statistically significant (p<0.05) in our study. However,
no pathogenic MYOC mutation was detected. A recent study
showed that a small proportion of PCG cases that do not
harbor CYP1B1 mutations exhibit a heterozygous mutation in
the  MYOC  gene  [16].  Digenic  inheritance  of  the  mutant
MYOC and CYP1B1 alleles has also been demonstrated in
juvenile-onset POAG and CYP1B1 has been suggested to be
a  modifier  of  MYOC  expression  [19].  The  heterozygous
p.Gln48His  MYOC  mutation  was  first  reported  in  two
sporadic cases of JOAG and an adult-onset POAG case from
eastern India. Later this change was also reported in a JOAG
family and in a sporadic POAG case from India [32].
Although IVS2+35G>A was not at splice location but
recent studies have revealed that intronic sequences may be
associated with gene regulation. Intronic mutation, therefore,
may be involved in the disease irrespective of whether the
mutated base was at splice site [33]. Two promoter sequence
variations (−126T>C and −83G>A) were observed in this
study. These variations do not alter any known promoter or
enhancer binding sites and are found in similar frequency in 
patients and controls [34]. There is no evidence from literature
that the −83G>A and −126T>C variations are associated with
either  the  steroid  response  or  POAG  [34].  Further,  the
majority (96%) of the steroid responders examined by Fingert
et al. [34] harbored no variations that met the criteria for
potential  involvement  in  the  steroid  response  phenotype,
clearly indicating that variations in the proximal promoter are
not a common cause of glaucoma. All these five changes of
MYOC  identified  in  this  study  are  listed  as  a  neutral
polymorphisms and no pathogenic variation in MYOC was
observed in this study.
Two changes (GGC375ins and GGC447ins) in FOXC1
were observed in cases as well as in controls. The frequency
of these FOXC1 variations were found to be statistically non-
significant (p>0.05) in our study. Both of these changes have
already  been  described  in  the  literature  as  neutral
polymorphisms [20,35,36]. The presence of mutations in the
FOXC1 gene in patients with PCG was initially described in
an independent study conducted by Chakrabarti et al. [20] in
2009 from south India. In addition, FOXC1 mutations have
been implicated in anterior segment dysgenesis (ASD) such
as iridogoniodysgenesis, Axenfeld-Rieger syndrome (ARS)
and Peter’s anomaly that progress to glaucoma in 50% to 75%
of cases [37-40]. Some of these ASD cases are associated with
congenital  or  early-onset  glaucomas,  whereas  some  have
glaucoma secondary to anterior segment anomalies [39-41].
Pathogenic FOXC1 mutations were identified in PCG cases
from southern India [20]. These findings indicate a potential
role of the transcription factor FOXC1 in the development of
ocular tissues including the drainage structures. Since neither
CYP1B1  nor  MYOC  could  explain  the  overall  genetic
contribution to PCG in earlier studies, we have also analyzed
FOXC1. However, no pathogenic mutations were identified
in MYOC and FOXC1 gene in our patients. It, therefore, gives
us a premise to assume the non-involvement of both MYOC
and FOXC1.
This difference in mutation spectrum of north Indian and
south Indian population may be explained on the basis of
different evolutionary history/ethnicity of both populations.
TABLE 3. MYOC GENE VARIATIONS IDENTIFIED IN THIS STUDY WITH P-VALUE AT 95% CONFIDENCE INTERVAL BY USING PEARSON χ2/FISHER’S EXACT TEST.
          Patient ID  
Serial
number
Location Sequence
change
Codon
change
Mutation PCG
(n=75)
Controls
(n=75)
p-value Odds Ratio (at 95%
CI)
1 Promoter −126T>C - - 2 0 0.496 -
2 Promoter −83G>A - - 9 2 0.055 4.97 (1.03–23.87)
3 Exon 1 c.227 G>A AGA>AAA p.R76K 30 12 0.001 3.50 (1.61–7.56)
4 Intron 2 IVS2+35 G>A - - 60 25 <0.001 8.00 (3.80–16.80)
5 Exon 3 c.1041T>C TAT>TAC p.Y347Y 5 0 0.058 -
TABLE 4. FOXC1 VARIATIONS IDENTIFIED IN THIS STUDY WITH P-VALUE AT 95% CONFIDENCE INTERVAL BY USING PEARSON χ2/FISHER’S EXACT TEST.
      Patient ID  
Serial number Sequence change Mutation PCG
(n=54)
Controls
(n=50)
p-value Odds ratio (at 95% CI)
1 Ins GCC GGC375ins 5 4 0.240 2.3 (0.66–8.00)
2 Ins CGG GGC447ins 6 5 1 1.12 (0.32–3.94)
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2004India has a heterogeneous population with people from north
and  south  India  being  ethnically  different.  The  ethno-
linguistic composition of the population of India, Pakistan,
Bangladesh, Nepal, Bhutan, Maldives, and Sri Lanka mostly
falls  within  two  large  groups;  Dravidian  and  Indo-Aryan.
These  groups  are  further  subdivided  into  numerous
subgroups,  castes,  and  tribes.  Indo-Aryans  form  the
predominant ethno-linguistic group in Pakistan, India (the
central, eastern, western, and northern regions), Nepal, Sri
Lanka, and the Maldives. Dravidians form the predominant
ethno-linguistic group in southern India and the northern and
eastern regions of Sri Lanka (The Indian Genome Variation
database  [IGVDb])  [42].  The  north  Indian  population  is
predominantly  Aryan  population  while  the  south  Indian
population is Dravidian with totally different morphological
phenotype  and  genetic  background.  Recently  it  has  been
shown that ‘Ancestral North Indians’ (ANI), are genetically
close to Middle Easterners, Central Asians, and Europeans,
whereas the other, the ‘Ancestral South Indians’ (ASI), is
distinct from ANI and East Asians as they are from each other
[43]. Thus, though mutations have been identified in MYOC
and FOXC1 in PCG cases from south India [16,20], these two
genes are not involved in PCG in our patients.
Conclusion:  This  is  the  first  study  from  north  India
showing  non-involvement  of  MYOC  and  FOXC1  in  the
pathogenesis  of  primary  congenital  glaucoma.  Thus,  it  is
important to screen other loci for involvement in congenital
glaucoma in cases which are either negative or heterozygous
for CYP1B1 mutations to have a better insight in disease
pathogenesis.
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